Non-opioid pain treatment NeuroRelease in development: 3 notes

The Medford, Mass.-based biotechnology company PixarBio is developing NeuroRelease, a non-opioid pain treatment. Representatives from the company discussed their product at New York School of Regional Anesthesia's annual symposium in New York City last weekend.

Here's what you need to know:

1. PixarBio advertises NeuroRelease as a "non-addictive and non-opiate treatment of pain," meant to replace morphine usage in surgical patients.

2. NeuroRelease affects a patient's sensory signals, rather than locomotion nerve fibers, to facilitate quick transition to physical therapy.

3. The company hopes to receive FDA approval for their 14-day postoperative pain treatment in 2018. The company also plans to offer four to eight hour, three day, seven day and 90 day pain treatments.

More articles on anesthesia:
White House promotes initiatives for Prescription Opioid and Heroin Epidemic Awareness Week: 5 notes
AANA stands in support of Prescription Opioid and Heroin Epidemic Awareness Week: 3 notes
NorthStar Anesthesia selects new EMR solution: 3 notes on Anesthesia Touch

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Featured Webinars

Featured Whitepapers